Spots Global Cancer Trial Database for A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
Official Title: A Phase 2 Open Label Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma Pretreated With One immunochecKPOint INhibiTor (Anti PD1/PDL1): the BREAKPOINT Trial
Study ID: NCT03463681
Conditions
Interventions
Study Description
Brief Summary: This is an open label single arm, multicenter, phase II study designet To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fondazione IRCCS Istituto Nazionale Tumori, Milan, , Italy
Contact Details
Name: Giuseppe Procopio, MD
Affiliation: Fondazione IRCCS ISTITUTO NAZIONALE TUMORI
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
